Literature DB >> 28123999

Living donor liver transplantation for hepatocellular carcinoma in Seoul National University.

Suk Kyun Hong1, Kwang-Woong Lee1, Hyo-Sin Kim1, Kyung Chul Yoon1, Nam-Joon Yi1, Kyung-Suk Suh1.   

Abstract

BACKGROUND: Liver transplantation is an effective treatment modality for hepatocellular carcinoma (HCC). Due to deceased organ shortage, living donor liver transplantation (LDLT) accounts for the majority of liver transplants in Korea. The aim of this study is to evaluate the recent trend of LDLT for HCC, and to suggest guidelines and criteria for selecting the appropriate candidates for LDLT.
METHODS: Between January 2000 and December 2015, 532 patients underwent LDLT for HCC. Clinicopathologic data were analyzed as well as overall survival rate (SR) and disease-free survival rate (DFSR) according to the Milan criteria based on explant pathology, positron emission tomography (PET) positivity, and serum alpha-fetoprotein (AFP) level.
RESULTS: The 5-year overall SR and DFSR were 81.5% and 75.5% respectively. According to our previously reported combination of AFP and PET [Seoul National University Hospital (SNUH) criteria]; low risk group [AFP <200 ng/mL, PET (-)], intermediate risk group [AFP >200 ng/mL, PET (-) or AFP <200 ng/mL, PET (+)], and high risk group [AFP >200 ng/mL, PET (+)], the 5-year DFSR of low risk group was 86.1%, intermediate risk group was 79.0%, and high risk group was 18.5% (P<0.001). Within the Milan criteria, the 5-year DFSR of low risk group was 88.4%, intermediate risk group was 79.9%, and high risk group was 60.0% (P=0.016). Beyond the Milan criteria, the 5-year DFSR of low, intermediate, and high risk group was 80.3%, 77.7%, and 9.1%, respectively (P<0.001).
CONCLUSIONS: In conclusion, our data and experience suggest that a continued paradigm shift from a conventional size based criteria to a biological marker based criteria is indicated when evaluating LDLT candidates with HCC.

Entities:  

Keywords:  Living donor liver transplantation (LDLT); Seoul National University Hospital criteria (SNUH criteria); hepatocellular carcinoma (HCC)

Year:  2016        PMID: 28123999      PMCID: PMC5218904          DOI: 10.21037/hbsn.2016.08.07

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  33 in total

1.  Global cancer statistics.

Authors:  D M Parkin; P Pisani; J Ferlay
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

2.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

3.  Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation.

Authors:  Ronnie Tung-Ping Poon; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; John Wong
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

4.  Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation.

Authors:  Carlos Margarit; Alfredo Escartín; Lluis Castells; Víctor Vargas; Elena Allende; Itxarone Bilbao
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

5.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

6.  Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus transplantation.

Authors:  Jean-Marc Bigourdan; Daniel Jaeck; Nicolas Meyer; Carole Meyer; Elie Oussoultzoglou; Philippe Bachellier; Jean-Christophe Weber; Maxime Audet; Michel Doffoël; Philippe Wolf
Journal:  Liver Transpl       Date:  2003-05       Impact factor: 5.799

Review 7.  Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.

Authors:  Markus Guba; Christian Graeb; Karl-Walter Jauch; Edward K Geissler
Journal:  Transplantation       Date:  2004-06-27       Impact factor: 4.939

8.  A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma.

Authors:  Sung Hoon Yang; Kyung-Suk Suh; Hae Won Lee; Eung-Ho Cho; Jai Young Cho; Yong Beom Cho; In Hwan Kim; Nam-Joon Yi; Kuhn Uk Lee
Journal:  Surgery       Date:  2007-03-23       Impact factor: 3.982

9.  Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?

Authors:  René Adam; Daniel Azoulay; Denis Castaing; Rony Eshkenazy; Gérard Pascal; Kentaro Hashizume; Didier Samuel; Henri Bismuth
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

10.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  13 in total

1.  Long non-coding RNA LINC00673 promotes hepatocellular carcinoma progression and metastasis through negatively regulating miR-205.

Authors:  Li-Guo Zhang; Xin-Ke Zhou; Ru-Jian Zhou; Hui-Zeng Lv; Wei-Peng Li
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Intrahepatic cholangiocarcinoma, are we making progress?

Authors:  Andre Gorgen; Nicolas Goldaracena; Wei Zhang; Gonzalo Sapisochin
Journal:  Hepatobiliary Surg Nutr       Date:  2018-04       Impact factor: 7.293

Review 3.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

Review 4.  Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?

Authors:  Jan Lerut; Samuele Iesari; Maxime Foguenne; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-10-12

5.  Efficacy of Liver Resection for Single Large Hepatocellular Carcinoma in Child-Pugh A Cirrhosis: Analysis of a Nationwide Cancer Registry Database.

Authors:  Suk Kyun Hong; Kwang-Woong Lee; Su Young Hong; Sanggyun Suh; Kwangpyo Hong; Eui Soo Han; Jeong-Moo Lee; YoungRok Choi; Nam-Joon Yi; Kyung-Suk Suh
Journal:  Front Oncol       Date:  2021-04-30       Impact factor: 6.244

6.  Preoperative albumin-bilirubin grade plus platelet-to-lymphocyte ratio predict the outcomes of patients with BCLC stage A hepatocellular carcinoma after liver resection.

Authors:  Chuan Li; Xiao-Yun Zhang; Wei Peng; Tian-Fu Wen; Lu-Nan Yan; Bo Li; Jia-Yin Yang; Wen-Tao Wang; Ming-Qing Xu; Li-Ping Chen
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

7.  Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.

Authors:  Seong Hee Kang; Hyeki Cho; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Nam-Joon Yi; Kwang-Woong Lee; Kyung-Suk Suh; Jung-Hwan Yoon
Journal:  J Korean Med Sci       Date:  2018-10-12       Impact factor: 2.153

8.  Selection of Hepatocellular Carcinoma Patients for Liver Transplantation: Should the Threshold for Expected Oncological Survival Be Lowered?

Authors:  Alessandro Giacomoni; Leonardo Centonze; Simone Famularo; Matteo Tripepi; Luciano DeCarlis
Journal:  Transplant Direct       Date:  2019-05-29

Review 9.  Recent advances in the surgical management of hepatocellular carcinoma.

Authors:  Georgios K Glantzounis; Anastasia Karampa; Dimitra V Peristeri; George Pappas-Gogos; Kostas Tepelenis; Petros Tzimas; Dimitrios J Cyrochristos
Journal:  Ann Gastroenterol       Date:  2021-05-27

10.  When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.

Authors:  Abu Bakar Hafeez Bhatti; Ammal Imran Qureshi; Rizmi Tahir; Faisal Saud Dar; Nusrat Yar Khan; Haseeb Haider Zia; Shahzad Riyaz; Atif Rana
Journal:  BMC Cancer       Date:  2020-08-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.